Circulating tumor DNA (ctDNA) negativity has been associated with prolonged response to treatment with immune checkpoint inhibitors (ICIs), researchers have found. While it is still too early for ctDNA to play a role in clinical practice, experts expressed enthusiasm for the future.
Health Professionals
Pharmacists Play Key Role in Managing Toxicity During Neoadjuvant Therapy for Melanoma
In a Pharmacy Times interview at the HOPA Annual Meeting 2025, Christine Barrett, PharmD, BCOP, clinical pharmacy specialist at West Virginia University, discussed the advantages of neoadjuvant therapy in melanoma, particularly the use of immunotherapy to leverage the tumor microenvironment and existing T-cell populations before surgery.
First Patient Receives KSQ-004EX for Advanced Cancer
A phase 1/2 trial evaluating KSQ-004EX, a novel CRISPR-engineered tumor infiltrating lymphocyte (eTIL) therapy, has dosed its first patient with an advanced solid tumor.
Advanced Melanoma at Diagnosis Associated With Several Patient-Specific Factors
Patients with certain sociodemographic factors are significantly more likely to present with advanced-stage melanoma at diagnosis, including those who live farther from treatment centers, those with Medicaid or without insurance, and those from lower-income households, among other factors. These study findings were published in SKIN.